Article
Medicine, General & Internal
Jon Danel Solano-Iturri, Enrique Echevarria, Miguel Unda, Ana Loizaga-Iriarte, Amparo Perez-Fernandez, Javier C. Angulo, Jose Lopez, Gorka Larrinaga
Summary: The study found that PRR is associated with the development and progression of renal tumors, with high expression at the tumor center and infiltrative front being significantly correlated with high grade, tumor diameter, local invasion, and stage, as well as high mortality risk. The potential of PRR as a novel biomarker for RCC diagnosis/prognosis and as a promising therapeutic target should be considered for the future.
Article
Medicine, Research & Experimental
Natalia K. S. Lima, Wilka R. A. Farias, Marry A. S. Cirilo, Angelica G. Oliveira, Juliane S. Farias, Regina S. Aires, Humberto Muzi-Filho, Ana D. O. Paixao, Leucio D. Vieira
Summary: Acute renal injury induced by ischemia-reperfusion may lead to changes in proximal tubule ATPases and RAAS components, which are associated with renal Na+ retention and hypertension. NADPH oxidase plays a key role in these alterations.
Review
Oncology
Xin Ouyang, Chuanming Xu
Summary: Cancer is a major global public health problem that affects hundreds of millions of people worldwide, and currently lacks reliable biomarkers for predicting its clinical outcomes. Recent research has shown that (pro)renin receptor (PRR) acts as a novel biomarker in various types of cancer. This review summarizes the current understanding of PRR in cancer, including its expression levels in different cancers, potential mechanisms in cancer progression, and its role in cancer treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Chuanming Xu, Chunju Liu, Jianhua Xiong, Jun Yu
Summary: Cardiovascular diseases are major public health problems globally and the activation of the (Pro)renin receptor (PRR) plays a significant role in cardiovascular homeostasis. PRR activation is associated with myocardial ischemia/reperfusion injury, cardiac hypertrophy, heart failure, vascular smooth muscle cell proliferation, endothelial cell dysfunction, and the progression of vascular diseases. Targeting PRR may have benefits for patients with cardiovascular diseases.
Article
Biochemistry & Molecular Biology
Hui Fang, Teng Yang, Baolong Zhou, Xinxuan Li
Summary: Chronic kidney disease (CKD) is associated with advanced oxidation protein products (AOPPs). A recent study investigated the role of the (pro)renin receptor (PRR) in AOPP-induced renal damage in rats. The study found that the PRR inhibitor PRO20 can protect against AOPP-induced nephropathy by inhibiting intrarenal renin-angiotensin system (RAS) and Nox4-derived H2O2 mechanisms.
Article
Cardiac & Cardiovascular Systems
Nirupama Ramkumar, Deborah Stuart, Caitlin S. Peterson, Chunyan Hu, William Wheatley, Jae Min Cho, J. David Symons, Donald E. Kohan
Summary: Loss of sPRR reduces baseline blood pressure, decreases Ang II-induced hypertension and renal injury, and is associated with greater endothelium-dependent vasorelaxation of resistance-sized arteries.
CIRCULATION RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Sam Siljee, Bridget Milne, Helen D. Brasch, Nicholas Bockett, Josie Patel, Paul F. Davis, Andrew Kennedy-Smith, Tinte Itinteang, Swee T. Tan
Summary: This study demonstrated the expression of PRR, ACE2, and AT(2)R by the CSCs within RCCC. Further studies may lead to novel therapeutic targeting of CSCs by manipulation of the RAS in the treatment of this aggressive cancer.
Article
Pharmacology & Pharmacy
Nadin Hoffmann, Joerg Peters
Summary: The (pro)renin receptor (P)RR has important roles in the kidney and brain, independently of prorenin, in activating inflammatory and fibrotic responses in renal dysfunction and being linked to hypertension in the brain. By regulating pH and function of v-ATPase, (P) RR plays crucial roles in cellular homeostasis and autophagy in kidney, brain, and heart.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Physiology
Jiajia Hu, Yandan Tan, Yanting Chen, Shiqi Mo, Brittin Hekking, Jiahui Su, Min Pu, Aihua Lu, Yanhua Du, J. David Symons, Tianxin Yang
Summary: This study demonstrates that activation of the (pro)renin receptor plays a role in cyclosporin A-induced nephropathy by activating the renin-angiotensin system. Antagonism with PRO20 is identified as a novel intervention in managing the side effects of cyclosporin A.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
(2022)
Article
Multidisciplinary Sciences
Shadi A. D. Mohammed, Hanxing Liu, Salem Baldi, Yu Wang, Pingping Chen, Fang Lu, Shumin Liu
Summary: Hypertension is a common chronic disease and a preventable risk factor for cardiovascular disease. Combination therapy using herbal medicine and antihypertensive agents shows positive effects in reducing blood pressure and improving vascular remodeling and renal protection. This study investigates the effects of Gedan Jiangya Decoction (GJD) combined with captopril (CAP) on spontaneously hypertensive rats (SHR) and demonstrates its antihypertensive, kidney protective, antioxidant, and vasoactive effects.
SCIENTIFIC REPORTS
(2023)
Review
Cardiac & Cardiovascular Systems
Boyang Wang, Haipeng Jie, Shuangxi Wang, Bo Dong, Yunzeng Zou
Summary: (Pro)renin receptor (PRR) is a component of the renin-angiotensin system (RAS) and is involved in the pathogenesis of cardiovascular diseases. This review focuses on the effects of PRR and its soluble form on various cardiovascular conditions, including hypertension, myocardial ischemia reperfusion injury, heart failure, metabolic cardiomyopathy, and atherosclerosis.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Multidisciplinary Sciences
Jonathan B. Murray, Christy Mikhael, Guanghong Han, Lorraine Perciliano de Faria, Wellington J. Rody, L. Shannon Holliday
Summary: The PRR abundant in extracellular vesicles shed by osteoclasts stimulates the activity of (pro)renin. This discovery reveals a novel mechanism for intercellular regulation by extracellular vesicles, with direct implications for bone biology.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Bettina Sehnert, Veronica Valero-Esquitino, Georg Schett, Thomas Unger, Ulrike Muscha Steckelings, Reinhard Edmund Voll
Summary: The selective non-peptide AT(2)R agonist Compound 21 (C21) has therapeutic potential in collagen-induced arthritis by promoting the expansion of CD4(+) regulatory T cells and suppressing IL-17A production.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Wanessa M. C. Awata, Arthur H. Sousa, Marcela M. B. de Mello, Thales M. H. Dourado, Lucas C. Pinheiro, Jefferson Elias-Oliveira, Vanessa F. Rodrigues, Daniela Carlos, Michele M. Castro, Carlos R. Tirapelli
Summary: Ethanol consumption leads to dysfunction of perivascular adipose tissue (PVAT) through the activation of the renin-angiotensin-aldosterone system (RAAS), particularly through the involvement of angiotensin II type 1 receptors (AT1R). This dysfunction involves reductions in the production of adiponectin and nitric oxide, resulting in impaired vasodilation and increased vascular contraction. These findings suggest that PVAT dysfunction may contribute to the hypertensive effects associated with ethanol consumption.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Integrative & Complementary Medicine
Na Song, Haitao Tu, Ying Li, Weijian Xiong, Ling Zhang, Hong Liu, Weisen Ding, Mei Long, Dewei Ren, Jin Zhong
Summary: By using network pharmacology, this study predicted the potential targets and pathways of Shen-Shuai-Ling Formulation (SSLF) for renal interstitial fibrosis (RIF). The binding of luteolin and target protein PLZF to SSLF was verified, and the effects of SSLF and luteolin on PLZF and (Pro) renin receptor (PRR) were examined. Both SSLF and luteolin upregulated the expression of PLZF and decreased the levels of PRR, Ang-1, Ang-2, and TGF-beta, thereby inhibiting PRR and renal interstitial fibrosis.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
(2022)